Danish pharmaceutical company DanCann Pharma's goal is to improve the lives of patients by providing medical cannabis and cannabinoids. Earlier this year, the company signed an agreement with
WEECO Pharma worth DKK 40 million and expects to reach its commercial breakthrough in the near future. To finance the next step in its development, it is now carrying out a share issue of DKK 28,5 million.
Se DanCann Pharmas vd Jeppe Krog Rasmussen present the company, in English, below.
Join us in beautiful Stockholm as we focus on early-, growth- and late-stage investments in life science. From business angels...
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Unlock our premium content: Become a subscriber!
Create Account
